FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and S ézary Syndrome

August 8, 2018 -- The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S ézary syndrome (SS) after...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news